Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

JAK2-V617F Promotes up-Regulation of Pro-Inflammatory Cytokines Including IL-1 upon Adhesion-Induced Activation of β1/β2 Integrins

Conny K. Baldauf, Emmanouil Charakopoulos, Martin Böttcher, Vanja Zeremski, Dimitrios Mougiakakos, Burkhart Schraven, Thomas Fischer

Blood (2023) 142 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2023-174058

Published: 2023

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Proteomic Profiling and Cytokine Analysis Reveals Molecular Signatures and Inflammatory Factors Associated with Thrombosis in JAK2-V617F Positive Myeloproliferative Neoplasm (MPN) Cohorts

Vikas Bhuria, Marco van Ham, Katrin Vogel, Ana Waldleben, Vanja Zeremski, Martin Böttcher, Monika Brunner-Weinzierl, Dimitrios Mougiakakos, Burkhart Schraven, Lothar Jänsch, Thomas Fischer

Blood (2023) 142 (Supplement 1): 6340.

https://doi.org/10.1182/blood-2023-174835

Published: 2023

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Tobias Ronny Haage, MD, Andreas Johann Müller, Priyadharshini Arunachalam, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2965.

https://doi.org/10.1182/blood-2019-122660

Published: 2019

Journal Articles

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Peter Müller, PhD, Bärbel Edelmann-Stephan, PhD, Fabian Richter, PhD, Klaus Pfizenmaier, PhD, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2966.

https://doi.org/10.1182/blood-2019-127997

Published: 2019

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Journal Articles

In Vivo Blockade of Beta-1 and Beta-2 Integrin Activity Inhibits Splenomegaly in JAK2-V617F Positive Myeloproliferative Disease

Linda Poschmann, Bärbel Edelmann-Stephan, PhD, Peter Müller, PhD, Frank Angenstein, MD, Thomas Fischer, MD

Blood (2018) 132 (Supplement 1): 1778.

https://doi.org/10.1182/blood-2018-99-114675

Published: 2018

Journal Articles

Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

Antonia Beitzen-Heineke, MD, Isabel Ben Batalla, PhD, Nikolaus Berenbrok, Sarina Paesler, Victoria Gensch, Gunhild von Amsberg, Philippe Schafhausen, MD, Kristoffer Riecken, PhD, Thomas Fischer, MD, Klaus Pantel, MD, PhD, Carsten Bokemeyer, MD, PhD, Sonja Loges, MD, PhD

Blood (2018) 132 (Supplement 1): 3063.

https://doi.org/10.1182/blood-2018-99-118175

Published: 2018

Journal Articles

Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors

Blood (2018) 132 (1): 67–77.

https://doi.org/10.1182/blood-2018-02-834895

Published: 2018

Includes: Supplemental data

Journal Articles

Comparison of Clinical Features and Outcomes in Patients with Primary Central Nervous System Lymphoma Treated within and Outside a Clinical Trial: A Retrospective Study

Vanja Zeremski, Thomas Fischer, Enrico Schalk

Blood (2017) 130 (Supplement 1): 1565.

https://doi.org/10.1182/blood.V130.Suppl_1.1565.1565

Published: 2017

Journal Articles

Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize FLT3(ITD)-Positive Acute Myeloid Leukemia Quiescent and Proliferative Cells to PARP Inhibitors

Blood (2017) 130 (Supplement 1): 2635.

https://doi.org/10.1182/blood.V130.Suppl_1.2635.2635

Published: 2017

Journal Articles

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Blood (2016) 128 (22): 1066.

https://doi.org/10.1182/blood.V128.22.1066.1066

Published: 2016

Journal Articles

Internal Tandem Duplication (ITD) in the Tyrosine Kinase Domain of FLT3 Displays Higher Oncogenic Potential in Acute Myeloid Leukemia

Alissa Marhäll, PhD student, Thomas Fischer, MD, Florian H. Heidel, MD, Julhash U. Kazi, PhD, Lars Rönnstrand, PhD

Blood (2016) 128 (22): 5118.

https://doi.org/10.1182/blood.V128.22.5118.5118

Published: 2016

Journal Articles

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Blood (2016) 128 (22): 516.

https://doi.org/10.1182/blood.V128.22.516.516

Published: 2016

Journal Articles

The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFB-MYH11

Kezhi Huang, Min Yang, Zengkai Pan, Florian H. Heidel, MD, Michaela Scherr, PhD, Matthias Eder, MD, Thomas Fischer, MD, Guntram Buesche, MD, Nils von Neuhoff, PhD, Arnold Ganser, MD, Zhixiong Li, MD

Blood (2015) 126 (23): 1383.

https://doi.org/10.1182/blood.V126.23.1383.1383

Published: 2015

Journal Articles

Expression of JAK2-V617F Kinase in Myeloid Progenitors and Proerythroblasts Induces Differential Patterns of Hypersensitivity in Activation of Key Signaling Nodes upon Incubation with Low-Dose, Physiologic EPO Concentrations

Christian Mueller, MD, Nibedita Gupta, PhD, Felix C Saalfeld, cand.MD, Rolf Findeisen, D.Eng, Nadine Rudolph, PhD, Steffen Klamt, D.Eng, Sandra Heise, graduate engineer, Fred Schaper, D.Sc, Thomas Fischer, MD

Blood (2014) 124 (21): 4573.

https://doi.org/10.1182/blood.V124.21.4573.4573

Published: 2014

NARROW

JAK2-V617F Promotes up-Regulation of Pro-Inflammatory Cytokines Including IL-1 upon Adhesion-Induced Activation of β1/β2 Integrins

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Proteomic Profiling and Cytokine Analysis Reveals Molecular Signatures and Inflammatory Factors Associated with Thrombosis in JAK2-V617F Positive Myeloproliferative Neoplasm (MPN) Cohorts

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

In Vivo Blockade of Beta-1 and Beta-2 Integrin Activity Inhibits Splenomegaly in JAK2-V617F Positive Myeloproliferative Disease

Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors

Comparison of Clinical Features and Outcomes in Patients with Primary Central Nervous System Lymphoma Treated within and Outside a Clinical Trial: A Retrospective Study

Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize FLT3(ITD)-Positive Acute Myeloid Leukemia Quiescent and Proliferative Cells to PARP Inhibitors

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Internal Tandem Duplication (ITD) in the Tyrosine Kinase Domain of FLT3 Displays Higher Oncogenic Potential in Acute Myeloid Leukemia

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFB-MYH11

Expression of JAK2-V617F Kinase in Myeloid Progenitors and Proerythroblasts Induces Differential Patterns of Hypersensitivity in Activation of Key Signaling Nodes upon Incubation with Low-Dose, Physiologic EPO Concentrations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only